<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339752</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-106</org_study_id>
    <nct_id>NCT03339752</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin</brief_title>
  <official_title>A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-541468 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy male subjects to investigate whether administration of ACT-541468 can
      affect the fate in the body (amount and time of presence in the blood) of rosuvastatin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">December 2, 2017</completion_date>
  <primary_completion_date type="Actual">December 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin</measure>
    <time_frame>During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.</time_frame>
    <description>Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin</measure>
    <time_frame>During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.</time_frame>
    <description>Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin</measure>
    <time_frame>During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.</time_frame>
    <description>Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin</measure>
    <time_frame>During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.</time_frame>
    <description>Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin</measure>
    <time_frame>During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.</time_frame>
    <description>Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) of ACT-541468</measure>
    <time_frame>During ACT-541468 administration (Treatment B1 and B2); i.e. for about 1 week</time_frame>
    <description>Trough concentration (Ctrough) of ACT-541468</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Change from baseline to each time point of measurement during each treatment in vital signs (supine BP and pulse rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG variables</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Change from baseline to each time point of measurement during each treatment in ECG variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent (serious) adverse events</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Treatment-emergent AEs and SAEs during each treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent ECG abnormalities</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Treatment-emergent ECG abnormalities during each treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Change from baseline to each time point of measurement during each treatment in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory tests</measure>
    <time_frame>From Screening to EOS (for a maximum of up to 5 weeks)</time_frame>
    <description>Change from baseline to each time point of measurement during each treatment in clinical laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-541468 Day 5 to Day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg tablet</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468</intervention_name>
    <description>25 mg hard capsule</description>
    <arm_group_label>Treatment B1</arm_group_label>
    <arm_group_label>Treatment B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in the local language prior to any study mandated procedure;

          -  Healthy male subjects aged 18 to 45 years (inclusive) at screening;

          -  Body mass index of 18.0 to 28.0 kg/m2 (inclusive) at screening;

          -  Healthy on the basis of physical examination, cardiovascular assessments and
             laboratory tests.

        Exclusion Criteria:

          -  Known allergic reactions or hypersensitivity to ACT-541468, rosuvastatin, any drug of
             the same classes, or any of their excipients;

          -  Any contraindication for rosuvastatin treatment;

          -  History or clinical evidence of myopathy;

          -  Asian or Indian-Asian ethnicity;

          -  Known hypersensitivity or allergy to natural rubber latex;

          -  Previous exposure to ACT-541468;

          -  Treatment with rosuvastatin within 3 months prior to screening;

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Mühlan</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cepha s.r.o.</name>
      <address>
        <city>Pilsen</city>
        <zip>32300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

